Introduction {#section6-1474515118786838}
============

Chronic heart failure is a progressive clinical syndrome characterised by recurrent episodes of worsening heart failure. Patients with chronic heart failure benefit from regular follow-up and monitoring of biometric measurements and heart failure symptoms to detect deterioration of heart failure and to ensure the safety and optimal dosing of heart failure medication.^[@bibr1-1474515118786838]^ However, deterioration of heart failure is unpredictable and often not fully captured in the fixed visits the patient has with his or her healthcare professional.

Telemonitoring is a promising technique that can detect early deteriorations in heart failure in order to avoid hospital admissions. However, clinical trials regarding the effectiveness of telemonitoring in managing heart failure care have produced mixed results, in part because of differences in the telemedicine approaches used.^[@bibr2-1474515118786838][@bibr3-1474515118786838]--[@bibr4-1474515118786838]^

In the last decades, non-invasive telemonitoring in heart failure has moved from structured telephone calls to remote management systems. In the case of remote management systems, data from telemonitoring devices is linked into a telemedical platform and send to the telemedical centre, hospitals or primary care provider.^[@bibr5-1474515118786838]^

One of the key components in non-invasive telemonitoring are biometric values (e.g. bodyweight, blood pressure and heart rate), measured on a regularly basis by patients at home.^[@bibr6-1474515118786838]^ The use of biometric measurements in non-invasive telemonitoring are based on the clinical presentation of patients with deterioration of heart failure, such as fluid overload (increased bodyweight), hypo- or hypertension, or brady- or tachyarrhythmias.

Besides biometric measurements, heart failure status questions are used for detection of deterioration and early intervention to prevent (re)hospitalization. The topics are mostly based on the clinical presentation of symptoms of deterioration of heart failure (e.g. dyspnoea, oedema).

To monitor the values in non-invasive telemonitoring programmes, there are several methods. The most commonly used method is based on manually reviewing biometric measurements by a healthcare provider, who is often helped by a protocol including thresholds and treatment plans. Another method is automated algorithms integrated in telemonitoring programmes.

At present, there is little evidence what combination of biometric measurements and questionnaires of self-reported symptoms is most effective in predicting deterioration of heart failure. Besides the combination, thresholds for these measurements are also less well studied. It stands to reason that when set too wide, then there is a high risk that the patient is decompensated before an alert trigger is generated whereas thresholds which are set too tightly could lead to many 'false' alert triggers.^[@bibr6-1474515118786838]^

The aim of this systematic review was, first, to assess how algorithms in non-invasive telemonitoring programmes were reported and, secondly, which subsequent thresholds for biometric parameters (bodyweight, blood pressure, heart rate) and symptom questions were used to monitor symptoms of heart failure and/or guide titration of heart failure medication.

Methods {#section7-1474515118786838}
=======

We undertook this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. See the PRISMA checklist in [Supplementary Material Appendix 1](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838).

Search strategy for identification of relevant studies {#section8-1474515118786838}
------------------------------------------------------

A comprehensive search was conducted through the MEDLINE (PubMed) and Embase ([www.embase.com](http://www.embase.com)) databases published until September 2017. Searched terms expressing heart failure were used in combination with terms identifying telemedicine. The full search strategy can be found in [Supplementary Material Appendix 2](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838). References of included studies were checked for additional relevant articles.

Review methods and selection criteria {#section9-1474515118786838}
-------------------------------------

Two reviewers (MB and SK) independently screened all titles and abstracts and made decisions regarding potential eligibility after full-text review. Discrepancies in judgment were resolved by a third reviewer (FA). We searched for articles written in English containing published reports of non-invasive telemedicine programmes (including telephone support) using biometric data performed in patients with heart failure aged over 18 years. We excluded publications: (a) addressing tele-rehabilitation only; (b) addressing tele-education only; (c) addressing telemonitoring programmes continuously collecting biometric data; (d) not monitoring patients at home; (e) not addressing an intervention.

Data extraction {#section10-1474515118786838}
---------------

For each included study, the following information was extracted: data source/study period, study location, number of hospitals, number of patients, study outcome, intervention, internal and external validity as reported by the authors.

Risk of bias in individual studies {#section11-1474515118786838}
----------------------------------

We performed risk of bias assessments using the 'Risk of bias' tool described in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (available from <http://handbook.cochrane.org>).^[@bibr7-1474515118786838]^ We assessed each study according to the following quality domains: random sequence generation, allocation concealment, participants and personnel were aware/unaware of the treatment assignments, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases ([Supplementary Material Appendix 3](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838)).

Summary measures and synthesis of results {#section12-1474515118786838}
-----------------------------------------

The process of data synthesis was performed through a descriptive analysis of the selected studies.

Results {#section13-1474515118786838}
=======

Article selection and risks of bias assessment {#section14-1474515118786838}
----------------------------------------------

The literature search (performed on 1 September 2017) identified 1457 publications in MEDLINE (*n*=1308) and Embase (*n*=149). Out of 99 studies that met the inclusion and exclusion criteria, 20 (20%) studies reported information on the algorithm used ([Figure 1](#fig1-1474515118786838){ref-type="fig"}). The detailed characteristics of the 20 studies that reported on the telemonitoring algorithm are presented in [Supplementary Material Appendix 4](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838). In 16 studies, data were automatically transferred to a telemonitoring service centre or trial site, and in four studies a mobile phone-based monitoring system was used.

![Flow of studies through the review process.](10.1177_1474515118786838-fig1){#fig1-1474515118786838}

No study was judged to be at low risk of bias ([Supplementary Material Appendix 3](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838)).

Biometric measurements and heart failure status questions in non-invasive telemonitoring programmes {#section15-1474515118786838}
---------------------------------------------------------------------------------------------------

The most frequently used biometric parameters in telemonitoring in heart failure were bodyweight (96%), blood pressure (85%), heart rate (61%), oxygen saturation (23%), and heart rhythm (17%) ([Figure 2](#fig2-1474515118786838){ref-type="fig"}). An electrocardiogram (ECG) (15%), holter (1%) or 15-second heart rhythm strip (1%) were used to detect the patient's heart rhythm. Less frequently used biometric parameters were heart and lungs auscultation (via electronic stethoscope) (7%), body temperature (6%), blood glucose (5%), respiration rate (2%), international normalized ratio (INR) (1%), measurement of ankle circumference with tape (1%), a six-minute walk test using a telemedical accelerometer (1%) and measuring steps a day with a pedometer (1%). In 42% of the articles, heart failure status questions were used in the algorithms such as 'Do you feel breathing is more difficult?', 'Have you felt more short of breath in the last day?' and 'Do you have any swelling in your hands or feet?' ([Supplementary Material Appendix 5](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838). Heart failure status questions in telemonitoring systems). In all heart failure status questionnaires at least one question concerning dyspnoea was included.^[@bibr8-1474515118786838][@bibr9-1474515118786838][@bibr10-1474515118786838][@bibr11-1474515118786838][@bibr12-1474515118786838][@bibr13-1474515118786838][@bibr14-1474515118786838]--[@bibr15-1474515118786838]^ A question concerning oedema was included in six questionnaires.^[@bibr8-1474515118786838],[@bibr9-1474515118786838],[@bibr11-1474515118786838],[@bibr13-1474515118786838][@bibr14-1474515118786838]--[@bibr15-1474515118786838]^

![Biometric parameters and heart failure (HF) symptoms measured in articles (%).](10.1177_1474515118786838-fig2){#fig2-1474515118786838}

Only Kurtz et al., in 2011, described the use of an algorithm based on a decision tree with numeric scores and a total score.^[@bibr12-1474515118786838]^ The algorithm contained three heart failure questions concerning bodyweight chance (answer possibilities: no change (zero points), change \<2 kg (one point), change \>2 kg (two points)), dyspnoea (answer possibilities: breath unchanged (zero points), more short of breath (one point)) and general health status (stable (zero points), deteriorated (one point)).^[@bibr12-1474515118786838]^

The Chronic Heart Failure Assessment by Telephone (CHAT) study used an algorithm including bodyweight and questions with regard to heart failure clinical status, medical management of the patient's condition and social questions relevant to the patient's heart failure status.^[@bibr8-1474515118786838]^ The algorithm contained the following modules: exercise, medicine adherence, dehydration, arrhythmia, appointment, excess body fluid.^[@bibr8-1474515118786838]^

In the study of Black et al., published in 2014, the thresholds set for biometric measurements were combined with alerts in heart failure status questions.^[@bibr11-1474515118786838]^ For example when a patient had a systolic blood pressure of \<90 mm Hg or \>160 mm Hg with symptoms, then an urgent alert was generated. Without symptoms, the systolic blood pressure threshold was \<80 mm Hg or \>170 mm Hg.^[@bibr11-1474515118786838]^

Biometric measurements and alert triggers {#section16-1474515118786838}
-----------------------------------------

The biometric measurements and the use of heart failure symptom questionnaires in the algorithm are shown in [Table 1](#table1-1474515118786838){ref-type="table"}. In the CHAT trial, heart failure status questions were specified but not the alert variance triggers of bodyweight (the only biometric parameter used in the study).^[@bibr8-1474515118786838]^ In 2007, in the study of Gambetta et al., alert triggers were set for absolute and relative changes in signs, reporting of symptoms, and noncompliance to medication.^[@bibr9-1474515118786838]^

###### 

Articles and alert triggers defined.

![](10.1177_1474515118786838-table1)

  Author                                                         Study             Weight          Blood pressure   Heart rate   Symptom questions   Medication adjustments and alert triggers bodyweight, blood pressure, heart rate
  -------------------------------------------------------------- ----------------- --------------- ---------------- ------------ ------------------- ----------------------------------------------------------------------------------
  **Biddis et al., 2009** ^[@bibr10-1474515118786838]^                             Yes             Yes              Yes          Yes                 --
  **Black et al., 2014** ^[@bibr11-1474515118786838]^            BEAT-HF           Yes             Yes              Yes          Yes                 --
  **Chaudhry et al., 2007** ^[@bibr13-1474515118786838]^         Tele-HF           Yes             --               --           Yes                 --
  **Cleland et al., 2005** ^[@bibr20-1474515118786838]^          TEN-HMS           Yes             Yes              Yes          --                  Yes, beta-blocker
  **Dendale et al., 2012** ^[@bibr22-1474515118786838]^          TEMA-HF           Yes             Yes              Yes          --                  --
  **Gambetta et al., 2007** ^[@bibr9-1474515118786838]^                            Yes             --               --           Yes                 --
  **Giordano et al., 2009** ^[@bibr23-1474515118786838]^                           Yes             Yes              --           --                  --
  **Hofmann et al., 2015** ^[@bibr27-1474515118786838]^          CardioBBEAT       Yes             Yes              Yes          --                  --
  **Krum et al., 2013**                                          CHAT              Not specified   --               --           Yes                 --
  **Kurtz et al., 2011** ^[@bibr12-1474515118786838]^                              Yes             --               --           Yes                 --
  **Lyngå et al., 2012** ^[@bibr18-1474515118786838]^            WISH              Yes             --               --           --                  --
  **Maric et al., 2010** ^[@bibr14-1474515118786838]^                              Yes             --               --           Yes                 --
  **Martín-Lesende et al., 2011** ^[@bibr17-1474515118786838]^   TELBIL            Yes             Yes              Yes          --                  --
  **Morguet et al., 2008** ^[@bibr26-1474515118786838]^                            Yes             Yes              Yes          --                  --
  **Piette et al., 2015** ^[@bibr25-1474515118786838]^                             Yes             --               --           --                  --
  **Roth et al., 2004** ^[@bibr19-1474515118786838]^                               Yes             Yes              --           --                  --
  **Scherr et al., 2009** ^[@bibr24-1474515118786838]^           MOBITEL           Yes             --               --           --                  --
  **Spaeder et al 2006** ^[@bibr21-1474515118786838]^                              --              Yes              Yes          --                  Yes, carvedilol
  **Wagenaar et al., 2015** ^[@bibr16-1474515118786838]^         E-Vita HF trial   Yes             Yes              Yes          --                  --
  **White-Williams et al., 2015** ^[@bibr15-1474515118786838]^                     Yes             Yes              Yes          Yes                 --

BEAT-HF: Better Effectiveness After Transition -- Heart Failure; CHAT: Chronic Heart Failure Assessment by Telephone; MOBITEL: MOBIle TELemonitoring in Heart Failure Patients; Tele-HF: Telemonitoring to Improve Heart Failure Outcomes; TEMA-HF: Telemonitoring in the Management of Heart Failure; TEN-HMS: Trans-European Network-Home-Care Management System; WISH: Weight monitoring in patients with severe heart failure.

In four articles authors noted physicians could change the biometric parameters, depending on the patient's status.^[@bibr10-1474515118786838],[@bibr11-1474515118786838],[@bibr16-1474515118786838],[@bibr17-1474515118786838]^

In most studies participants were asked to measure the biometric parameters daily ([Table 2](#table2-1474515118786838){ref-type="table"}). The biometric alert triggers used in the articles are listed in [Table 2](#table2-1474515118786838){ref-type="table"}, the used heart failure status questions are in [Supplementary Material Appendix 5](http://journals.sagepub.com/doi/suppl/10.1177/1474515118786838).

###### 

Alert triggers of bodyweight, blood pressure, heart rate.

![](10.1177_1474515118786838-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                         Study                  Bodyweight variance alert triggers                                                                                                                                                                                                                                                                                                                   Blood pressure (mm Hg)                                                                Heart rate, beats/min                          Frequency                                                                             
  -------------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------- -------------
  **Biddis et al., 2009** ^[@bibr10-1474515118786838]^                                  Increase 0.91 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ since previous day or if weight increases by 1.36 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ in a rolling 7 days                                                                                                                                              \<100 or drops by 20 from previous reading                                            --                                             \<55 or \>120                                                                         Daily

  **Black et al., 2014** ^[@bibr11-1474515118786838]^            BEAT-HF                With symptoms^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^\                                                                                                                                                                                                                                                                                With symptoms^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ \<90 or \>160\   --                                             With symptoms^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ \<50 or \>100\   Daily
                                                                                        Daily gain \>1.36 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ or weekly gain \>2.72 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^                                                                                                                                                                                          Without symptoms\                                                                                                                    Without symptoms \<40 or \>110                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                             \<80 or \>170                                                                                                                                                                                                              

  **Chaudhry et al., 2007** ^[@bibr13-1474515118786838]^         Tele-HF                \>1.36 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ above or below first bodyweight entered                                                                                                                                                                                                                                             --                                                                                    --                                             --                                                                                    Daily

  **Cleland et al., 2005** ^[@bibr20-1474515118786838]^          TEN-HMS                \>2 kg weight gain                                                                                                                                                                                                                                                                                                                                   \<90 or \>140                                                                         --                                             Resting heart rate \<50 or \>80                                                       Twice daily

  **Dendale et al., 2012** ^[@bibr22-1474515118786838]^          TEMA-HF                +2 kg from discharge bodyweight                                                                                                                                                                                                                                                                                                                      \<90 or \>140                                                                         --                                             \<50 or \>90                                                                          Daily

  **Gambetta et al., 2007** ^[@bibr9-1474515118786838]^                                 A weight change of 1.36 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ in 3 days                                                                                                                                                                                                                                                          --                                                                                    --                                             --                                                                                    Daily

  **Giordano et al., 2009** ^[@bibr23-1474515118786838]^                                Increase \>2 kg                                                                                                                                                                                                                                                                                                                                      Dizziness with \<90                                                                   --                                             --                                                                                    Daily

  **Hofmann et al., 2015** ^[@bibr27-1474515118786838]^          Cardio-\               \>2 kg within 3 days                                                                                                                                                                                                                                                                                                                                 \<90 or \>140                                                                         --                                             Resting heart rate \<50 or \>80                                                       Daily
                                                                 BBEAT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Krum et al., 2013** ^[@bibr8-1474515118786838]^              CHAT                   Not specified                                                                                                                                                                                                                                                                                                                                        --                                                                                    --                                             --                                                                                    ⩾Monthly

  **Kurtz et al., 2011** ^[@bibr12-1474515118786838]^                                   Weight change \<2 kg\                                                                                                                                                                                                                                                                                                                                --                                                                                    --                                             --                                                                                    Weekly
                                                                                        or \>2 kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Lyngå et al., 2012** ^[@bibr18-1474515118786838]^            WISH                   \>2 kg weight gain in 3 days                                                                                                                                                                                                                                                                                                                         --                                                                                    --                                             --                                                                                    Daily

  **Maric et al., 2010** ^[@bibr14-1474515118786838]^                                   Weight changed ⩾2 kg in 2 days, ⩾5 kg in 7 days                                                                                                                                                                                                                                                                                                      --                                                                                    --                                             --                                                                                    Daily

  **Martín-Lesende et al., 2011** ^[@bibr17-1474515118786838]^   TELBIL                 \>1 kg within 3 days                                                                                                                                                                                                                                                                                                                                 \<100 or \>160                                                                        \<60 or \>90                                   \<50 or \>100                                                                         Daily

  **Morguet et al., 2008** ^[@bibr26-1474515118786838]^                                 \>1.5 kg                                                                                                                                                                                                                                                                                                                                             \<90 or \>180                                                                         \>110                                          --                                                                                    Daily

  **Piette et al., 2015** ^[@bibr25-1474515118786838]^                                  Increase of 2.27 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ over 1 or 2 weeks, a 3.18 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ increase over 3 weeks, or an average gain of 0.91 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ per week since the last automated call if more than 3 weeks had elapsed   --                                                                                    --                                             --                                                                                    Daily

  **Roth et al., 2004** ^[@bibr19-1474515118786838]^                                    \>1.5 kg compared to baseline                                                                                                                                                                                                                                                                                                                        \<90 or \>180                                                                         \>110                                          --                                                                                    Daily

  **Scherr et al., 2009** ^[@bibr24-1474515118786838]^           MOBITEL                Increased or decreased more than 2 kg in 2 days                                                                                                                                                                                                                                                                                                      --                                                                                    --                                             --                                                                                    Daily

  **Spaeder et al., 2006** ^[@bibr21-1474515118786838]^          Carvedilol titration   \-                                                                                                                                                                                                                                                                                                                                                   Between 85--99                                                                        --                                             Between 55--64                                                                        Daily

  **Wagenaar et al., 2015** ^[@bibr16-1474515118786838]^         E-Vita HF trial        +1 kg in 1 day, +2 kg in three consecutive days, --3 kg in 1 day and +2 kg or −2 kg from baseline bodyweight)                                                                                                                                                                                                                                        Average \<90 or \>140 for 3 consecutive days                                          Average \<50 or \>100 for 3 consecutive days   \<50 or \>100                                                                         Daily

  **White-Williams et al., 2015** ^[@bibr15-1474515118786838]^                          \>2.27 kg^[a](#table-fn3-1474515118786838){ref-type="table-fn"}^ increase                                                                                                                                                                                                                                                                            Vary \>10 mm Hg                                                                       Vary \>10 mm Hg                                \<60 or \>120                                                                         Daily
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BEAT-HF: Better Effectiveness After Transition -- Heart Failure; CHAT: Chronic Heart Failure Assessment by Telephone; MOBITEL: MOBIle TELemonitoring in Heart Failure Patients; Tele-HF: Telemonitoring to Improve Heart Failure Outcomes; TEMA-HF: Telemonitoring in the Management of Heart Failure; TEN-HMS: Trans-European Network-Home-Care Management System; WISH: Weight monitoring in patients with severe heart failure.

Pounds to kilogram conversion (1 lb=0.45359237 kg).

Monitoring of data by healthcare professionals {#section17-1474515118786838}
----------------------------------------------

In 11 studies, alert triggers were monitored by a nurse.^[@bibr8-1474515118786838],[@bibr9-1474515118786838],[@bibr11-1474515118786838],[@bibr14-1474515118786838],\ [@bibr16-1474515118786838][@bibr17-1474515118786838][@bibr18-1474515118786838][@bibr19-1474515118786838][@bibr20-1474515118786838][@bibr21-1474515118786838]--[@bibr22-1474515118786838]^ In one study both the general practitioner and healthcare professionals at the heart failure clinic monitored the data.^[@bibr23-1474515118786838]^ In five studies it was less specifically described who monitored the data, because of the use of the general terms 'clinician' and 'physician'.^[@bibr10-1474515118786838],[@bibr13-1474515118786838],[@bibr15-1474515118786838],[@bibr24-1474515118786838],[@bibr25-1474515118786838]^ In three studies the healthcare professional (e.g. physician, nurse) who monitored the biometric values remained unclear.^[@bibr12-1474515118786838],[@bibr26-1474515118786838],[@bibr27-1474515118786838]^ The frequency of monitoring biometric measurements varied between daily and three times a week.

Actions of healthcare professionals on alert triggers {#section18-1474515118786838}
-----------------------------------------------------

In 12 studies, patients were contacted by telephone in the case of measurements outside thresholds.^[@bibr11-1474515118786838],[@bibr13-1474515118786838][@bibr14-1474515118786838][@bibr15-1474515118786838][@bibr16-1474515118786838][@bibr17-1474515118786838][@bibr18-1474515118786838]--[@bibr19-1474515118786838],[@bibr23-1474515118786838],[@bibr24-1474515118786838],[@bibr26-1474515118786838],[@bibr27-1474515118786838]^ In the CardioBBEAT trial, the study site called the patient if questionnaires revealed potential deterioration.^[@bibr27-1474515118786838]^ The telemedicine centre called the patient if biometric measurements were outside of the established limits. In six studies, it remained unclear how health professionals contacted patients (visits, telephone calls).^[@bibr8-1474515118786838][@bibr9-1474515118786838]--[@bibr10-1474515118786838],[@bibr20-1474515118786838],[@bibr21-1474515118786838],[@bibr25-1474515118786838]^ In the Telemonitoring in the Management of Heart Failure (TEMA-HF) study a general practitioner visited or contacted the patient if the general practitioner considered it necessary. The heart failure nurse called the patient 1--3 days after the alert.^[@bibr22-1474515118786838]^ Kurtz et al., in 2011, used an automated self-monitoring system.^[@bibr12-1474515118786838]^ When measurements were stable (zero points) the patients were asked to repeat the measurements after a week, in the case of minor worsening (one point) after three days, in the case of suspected deterioration of heart failure (two points) to proceed a medical visit or to increase the frequency of telephone contacts and inform the patient's physician, in the case of high risk of hospitalization (three points) according to the algorithm the patient were directly connected to a heart failure clinic healthcare professional.^[@bibr12-1474515118786838]^ The actions taken by healthcare professionals who contacted the patients after an alert trigger varied between changes in medication treatment (in consultation with a cardiologist or with a general practitioner), further investigations or a scheduled consult of a cardiologist, nurse or general practitioner (deterioration of heart failure). The telemedicine system was checked again on schedule within 2--3 days. In five studies (25%) it remained unclear which actions were taken after contacting the patient in the case of stable or deterioration of heart failure.^[@bibr8-1474515118786838][@bibr9-1474515118786838]--[@bibr10-1474515118786838],[@bibr17-1474515118786838],[@bibr25-1474515118786838]^

Medication protocols {#section19-1474515118786838}
--------------------

Changes in heart failure medication in the case of alert triggers remained unclear in most of the studies. In the WISH trial patients were asked to take an additional dose of their diuretics in the case of deterioration of heart failure.^[@bibr18-1474515118786838]^ The CHAT trial used a diuretic protocol, but did not further specify the protocol.^[@bibr8-1474515118786838]^ In the Trans-European Network-Home-Care Management System (TEN-HMS) trial a heart rate of ⩽65 bpm during the titration phase was an indication to delay further increase in dose of beta-blocker.^[@bibr20-1474515118786838]^ The study of Spaeder et al., in 2006, consisted of rapid titration of carvedilol using a telemedical system versus frequent outpatient heart failure clinic visits.^[@bibr21-1474515118786838]^

Discussion {#section20-1474515118786838}
==========

In the present study, we assessed thresholds of algorithms in non-invasive telemonitoring programmes for symptoms of heart failure. First and foremost, we found that only one in five telemonitoring studies specified the algorithm used to monitor heart failure symptoms. The thresholds used for alert triggers in bodyweight, blood pressure and heart rate varied. Furthermore, the level of precision in measurement of bodyweight, blood pressure and heart rate remained unclear. With regard to heart failure status questionnaires, there was a wide range of topics and number of questions asked. Lastly, in the included articles, there was considerable heterogeneity in describing telemonitoring programmes and protocols.

The most common biometric measurement in telemonitoring was bodyweight and was mostly combined with other biometric measurements such as blood pressure or with heart failure status questions.

In most studies nurses interpreted the data.^[@bibr8-1474515118786838],[@bibr9-1474515118786838],[@bibr11-1474515118786838],[@bibr14-1474515118786838],[@bibr16-1474515118786838][@bibr17-1474515118786838][@bibr18-1474515118786838][@bibr19-1474515118786838][@bibr20-1474515118786838][@bibr21-1474515118786838]--[@bibr22-1474515118786838]^ Some articles used general terms as 'clinician' or 'physician' to indicate the healthcare professional monitoring the data and in three studies it remained unclear who interpreted the data. In most cases little information was given about the educational background of the healthcare professional monitoring the data concerning heart failure and interpretation of telemonitoring values. Thereby the relationship between knowledge and experience at monitoring data and effectiveness of a telemonitoring programme remains unclear. It may be valuable to report in articles the profession of the healthcare professional and in the case of nurses if they were specialised in heart failure and if he/she was educated in monitoring biometric data. Even though there is a wide diversity in nursing education in heart failure and in organization of heart failure care, within and between countries, this could help to interpret the findings of scientific research.^[@bibr28-1474515118786838],[@bibr29-1474515118786838]^

Furthermore, the description of the actions taken in the case of an alert trigger can be informative. In six studies it remained unclear how healthcare professionals contacted patients in the case of an alert trigger (visits, telephone calls, video consult), which subsequent actions were taken (fixing a new scheduled appointed (stable conditions) and if medication were changed (e.g. in consultation with cardiologist or with general practitioner).^[@bibr8-1474515118786838][@bibr9-1474515118786838]--[@bibr10-1474515118786838],[@bibr20-1474515118786838],[@bibr21-1474515118786838],[@bibr25-1474515118786838]^ In these studies it remained unclear how the actions taken on alert triggers affected the findings of the trial.

Underreported in articles were medication titration protocols used in telemonitoring programmes in heart failure. In one study, the TEN-HMS study, a threshold for heart rate was reported to delay further increase in dose of betablocker.^[@bibr20-1474515118786838]^ Medication titration algorithms for angiotensin-converting-enzyme inhibitor (ACEi), angiotensin II inhibitor (ARB), beta-blockers, mineralocorticoid receptor antagonists (MRAs) were not identified. The WISH and CHAT studies reported loop diuretic adjustments, but did not specify them.^[@bibr8-1474515118786838],[@bibr18-1474515118786838]^ As medication protocols remain underexposed in telemedicine articles, the effects of medication changes on the results of telemedicine studies remain to be elucidated.

In the field of telemonitoring of heart failure, the view is arising that it is of paramount importance to increase comparability between telemonitoring studies.^[@bibr2-1474515118786838][@bibr3-1474515118786838]--[@bibr4-1474515118786838]^ Not only the description of both the intervention (e.g. telemedical system used, contacts with healthcare professionals) and usual care provide important information, but also algorithms, level of precision in measurement of biometric equipment, information about monitoring data and actions taken on values outside thresholds provide meaningful insights. The importance of specifying telemonitoring algorithms may be seen to be particularly helpful for the monitoring of bodyweight. Monitoring of daily bodyweight is recommended in chronic heart failure and there is substantial heterogeneity in published rule-of-thumb thresholds that define clinically important bodyweight gain that can indicate deterioration of heart failure.^[@bibr30-1474515118786838]^ Several research groups reported that simple rules of sudden bodyweight change in patients with heart failure were demonstrated to generate many alerts with poor sensitivity.^[@bibr6-1474515118786838],[@bibr30-1474515118786838][@bibr31-1474515118786838]--[@bibr32-1474515118786838]^

Different methods are being used to interpret values outside thresholds in telemonitoring chronic heart failure. Some telemonitoring programmes depend only on know-ledge of the healthcare professional interpreting the data. Other telemonitoring programmes use automated algorithms to monitor data and issue an alarm in the case of values outside the established thresholds. The healthcare professional subsequently interprets the alarm and decides which actions to take (with or without use of a protocol).

Most of the automated algorithms used in monitoring early deterioration of heart failure are decision-tree and threshold-based. In the nearby future, more personalised self-learning automated algorithms (machine-learning methods) will likely be used in monitoring early deterioration of heart failure.

Study limitations {#section21-1474515118786838}
-----------------

The systematic review was limited by the amount and nature of the data available. We limited the review to fully published studies.

Conclusions {#section22-1474515118786838}
===========

Only one in five studies on non-invasive telemonitoring of chronic heart failure reported the algorithm that was used to detect worsening heart failure. The most commonly used biometric parameter in non-invasive telemonitoring in heart failure is bodyweight. Standardised description of the telemonitoring algorithm can expedite the identification of key components in telemonitoring algorithms that allow accurate prediction of worsening heart failure.
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Implications for practiceLittle is known about algorithms used to detect deterioration of heart failure. Standardised reporting of algorithms used and the actions taken on alarms can help to compare telemonitoring programmes more effectively.It may be valuable to report in articles the profession of the healthcare professional and in the case of nurses whether they were specialised in heart failure and if educated in monitoring biometric data.As medication protocols remain underexposed in telemedicine articles, the effect of medication changes on the results of telemedicine studies remains to be elucidated.
